Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d21cbff64022f95c237c0bd3ec8656ca |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-812 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-31 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-468 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2863 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-22 |
filingDate |
2019-05-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_27ae5e705c11119d87b6bfd086f23ead http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_52a39ab803cd167d0d176a36c6972aa1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d56ef3d58c70da3c559d9f60d62772b4 |
publicationDate |
2019-12-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
WO-2019232323-A1 |
titleOfInvention |
Bi-specific antibodies and use thereof |
abstract |
The present disclosure provides a bispecific antibody comprising an IgG linked to an scFv, wherein the VH domain of the IgG is linked to the VH domain of the scFv, the bispecific antibody binding a human vascular endothelial growth factor (VEGF) family protein and an epidermal growth factor receptor (EGFR) family protein. Further embodiments provide pharmaceutical compositions comprising the bispecific antibody of the embodiments and aspects thereof and a pharmaceutically acceptable carrier. Further embodiments provide various methods of treating cancer in a subject comprising administering a bispecific antibody of the embodiments and aspects thereof to the subject. A further embodiment provides a kit comprising the bispecific antibody. |
priorityDate |
2018-05-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |